ALLO (STOCKS)
Allogene Therapeutics, Inc. Common Stock
$1.960000
+0.060000 (+3.16%)
Prev close: $1.900000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- David D. Chang
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $676.50M
- Employees
- 361
- P/E (TTM)
- -2.47
- P/B (TTM)
- 1.67
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
10
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.18 | $-0.19 | +0.0142 | +7.31% |
|
Dec 2025 (Q4)
|
$-0.17 | $-0.22 | +0.0507 | +22.97% |
|
Sep 2025 (Q3)
|
$-0.19 | $-0.23 | +0.0377 | +16.56% |
|
Jun 2025 (Q2)
|
$-0.23 | $-0.28 | +0.0490 | +17.56% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $16.46M |
| Operating Expenses | $190.22M |
| Research and Development | $131.96M |
| Other Operating Expenses | $58.26M |
| Operating Income/Loss | -$190.22M |
| Income/Loss From Continuing Operations After Tax | -$173.76M |
| Income/Loss From Continuing Operations Before Tax | -$173.76M |
| Net Income/Loss | -$173.76M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$173.76M |
| Net Income/Loss Available To Common Stockholders, Basic | -$173.76M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.77 |
| Diluted Earnings Per Share | -$0.77 |
| Basic Average Shares | 245,554,832 |
| Diluted Average Shares | 245,554,832 |
| Assets | $395.96M |
| Current Assets | $273.29M |
| Cash | $266.90M |
| Other Current Assets | $6.39M |
| Noncurrent Assets | $122.67M |
| Fixed Assets | $70.02M |
| Other Non-current Assets | $52.64M |
| Liabilities | $117.08M |
| Current Liabilities | $28.33M |
| Accounts Payable | $4.93M |
| Other Current Liabilities | $23.40M |
| Noncurrent Liabilities | $88.75M |
| Equity | $278.88M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $278.88M |
| Liabilities And Equity | $395.96M |
| Net Cash Flow From Operating Activities | -$109.23M |
| Net Cash Flow From Operating Activities, Continuing | -$109.23M |
| Net Cash Flow From Investing Activities | $59.80M |
| Net Cash Flow From Investing Activities, Continuing | $59.80M |
| Net Cash Flow From Financing Activities | $37.29M |
| Net Cash Flow From Financing Activities, Continuing | $37.29M |
| Net Cash Flow | -$12.15M |
| Net Cash Flow, Continuing | -$12.15M |
| Comprehensive Income/Loss | -$173.90M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$173.90M |
| Other Comprehensive Income/Loss | -$41.54M |